Vedolizumab (Entyvio) SC Approved for Maintenance Therapy in Adults with Moderately to Severely Active Crohn Disease
Vedolizumab for subcutaneous injection in now indicated for maintenance therapy following IV induction in both Crohn disease and ulcerative colitis.
Advanced-Stage CKD Prevalence Quickly Rising Worldwide: Daily Dose
Your daily dose of the clinical news you may have missed.
ACP Recommends SGLT2i, GLP1 RA After Metformin to Manage Cardiorenal Comorbidities in Adults with Type 2 Diabetes
Based on the classes' cardio- and renoprotective benefits, the ACP recommends SGLT2i and GLP1RA as second-line therapy in adults with T2D who are most likely to benefit.
After the CLEAR Outcomes Trial, ASCVD Risk Reduction Remains a Global Challenge, PI Nissen Says
The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.
Bempedoic Acid Should be In Everyone's CVD Prevention Toolbox, According to Steven Nissen, MD
Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.
Untreated, New-Onset Hypertension Tied to Higher Risk of Uterine Fibroids in Women
Women with new-onset HTN faced a 45% greater risk of newly self-reported fibroids and those with untreated HTN had a 19% greater risk, according to a new study.
FDA Approves Benralizumab as Add-On Maintenance Therapy for Children with Severe Asthma: Daily Dose
Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD
Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.
Steven Nissen, MD, Discusses the "Sweet Spot" for Bempedoic Acid Among Non-Statin Therapies
The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.
Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination
Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.
RSV Disease Severity Comparable to Unvaccinated COVID-19, Flu: Daily Dose
8 Questions on Management of Chronic Coronary Disease: A Guideline Topline Quiz
Based on the updated 2023 AHA/ACC recommendations, the 9-question quiz tests what you know about the most current approaches to CCD treatment.
How the CLEAR Outcomes Trial Made CV Risk Reduction History, with Lead Investigator Steven Nissen, MD
Bempedoic acid became the first nonstatin LDL-C lowering medication indicated to reduce CV risk in both primary and secondary prevention. Nissen explains how.
Risk for CHD Higher for Women who Binge Drink vs Men: Daily Dose
Navigating the New Wave of Antiobesity Medications: What Primary Care Clinicians Should Know
With the rise in demand for newer antiobesity medications, clinicians may face more questions from patients. Here, a primer on the drawbacks and benefits to keep in mind.
Tirzepatide Significantly Reduces OSA Symptoms in Phase 3 Trials, Lilly Looks Toward Mid-2024 Regulatory Submission
Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.
Tezepelumab for COPD Moves into Phase 3 Planning
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA
The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.
Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort
Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.
Zilebesiran Reduces SBP on Background SOC in Uncontrolled HTN: Daily Dose
